FDA clears first at-home brain-stimulation device for depression

Depression affects hundreds of millions of people, yet many cannot tolerate antidepressant medication or do not respond to it. On December 11, 2025, the US Food and Drug Administration cleared a new option: the FL-100 from Flow Neuroscience, the first at-home brain-stimulation device authorized in the United States to treat major depressive disorder, offered as a non-drug therapy.

The FL-100 is a wearable headset that delivers transcranial direct current stimulation, or tDCS, a gentle electrical current applied to the brain's left dorsolateral prefrontal cortex, an area involved in mood regulation. The mild current is thought to help neurons there fire more effectively and rebalance mood-related chemistry. Patients use it at home over a roughly ten-week course, supported by a companion smartphone app, rather than traveling to a clinic.

“On December 11, 2025, the US Food and Drug Administration cleared a new option: the FL-100 from Flow Neuroscience, the first at-home brain-stimulation device authorized in the United States to treat major depressive disorder, offered as a non-drug therapy.”

The clinical and real-world signals are encouraging. The clearance was based on trial data showing clinically meaningful symptom reduction, often appearing within three weeks, with minimal side effects. Flow reports that among real-world users, 77 percent see improvements in as little as three weeks. Chief medical officer Dr. Kultar Garcha cited that figure, while CEO Erin Lee called the approval a "watershed moment for depression treatment" and a first step toward "tech-based therapies with minimal side effects." The device, already certified and used by tens of thousands of people across the UK and Europe, is expected to launch in the US in the second quarter of 2026.

The honest caveats are important. tDCS does not work for everyone, the device is prescription-based and meant to be used under medical guidance, and it is not a wholesale replacement for medication or talk therapy, which remain right for many patients. Long-term outcomes across diverse populations will continue to be studied. Even so, a safe, drug-free treatment that people can use in their own homes could expand access for those failed by existing options and reduce the stigma and barriers around mental-health care. For a condition this widespread, a new and gentle tool is genuinely hopeful news.